SCHEMBL2364512

SCHEMBL2364512

CN1CCN(c2ncc(-c3cccc(Nc4ccc(Cl)cc4)n3)o2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WEE1 P30291 3/20 0.42
HTR2C P28335 2/20 0.41
HTR2A P28223 1/20 0.41
FGFR1 P11362 1/20 0.40
SRC P12931 1/20 0.40
AURKA O14965 1/20 0.40
KDM1A O60341 1/20 0.39
ALK Q9UM73 1/20 0.39
EGFR P00533 2/20 0.39
JAK2 O60674 1/20 0.39
JAK3 P52333 1/20 0.39
BRD4 O60885 2/20 0.39
LCK P06239 1/20 0.38
MAPK14 Q16539 1/20 0.38
ERBB3 P21860 1/20 0.38
FYN P06241 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
FLT3 P36888 1/20 0.37
CNR2 P34972 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14673765 0.88 ABL1 (0.39) WEE1FLT3CNR2
SCHEMBL14673902 0.84 JAK2 (0.52) EGFRJAK2JAK3BRD4RAB9A
SCHEMBL2227650 0.82 AOC3 (0.37) WEE1EGFRERBB3CNR2
SCHEMBL2226024 0.81 USP2 (0.51) AURKAEGFRBRD4FYN
SCHEMBL13825903 0.81 KCNH2 (0.43) EGFRJAK2JAK3RAB9AKMT2A
SCHEMBL27899683 0.81 CCNK (0.43) AURKALCKKMT2AFLT3CNR2
SCHEMBL2363760 0.79 KCNH2 (0.42) SRCAURKAJAK2KMT2AFLT3
SCHEMBL14673616 0.79 KARS1 (0.52) EGFRJAK2JAK3
SCHEMBL14674242 0.78 RAB9A (0.40) RAB9AKMT2A
SCHEMBL2352796 0.78 GRM5 (0.41) LCKRAB9AKMT2AFLT3CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2523952-B1 OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2015-03-04 EP claimed
US-8962665-B2 Thiazole and oxazole kinase inhibitors AB SCIENCE (FR) 2015-02-24 US claimed
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2013-02-07 US claimed
CN-102812022-A Thiazole and oxazole kinase inhibitors AB SCIENCE 2012-12-05 CN claimed
EP-2523952-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB Science (FR) 2012-11-21 EP claimed
WO-2011086085-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2011-07-21 WO claimed
EP-2523952-B1 OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2015-03-04 EP disclosed
US-8962665-B2 Thiazole and oxazole kinase inhibitors AB SCIENCE (FR) 2015-02-24 US disclosed
US-8962665-B2 Thiazole and oxazole kinase inhibitors AB SCIENCE (FR) 2015-02-24 US disclosed
US-8962665-B2 Thiazole and oxazole kinase inhibitors AB SCIENCE (FR) 2015-02-24 US disclosed
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2013-02-07 US disclosed
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2013-02-07 US disclosed
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2013-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SYK, LTK, MERTK WEE1 296/4885HTR2C 2548/4885HTR2A 3723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.